- Home
- SUNE vs MBRX Comparison
SUNE vs MBRX Comparison
Compare SUNE & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUNE
- MBRX
- Stock Information
- Founded
- SUNE 1969
- MBRX 2015
- Country
- SUNE United States
- MBRX United States
- Employees
- SUNE N/A
- MBRX N/A
- Industry
- SUNE
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- SUNE
- MBRX Health Care
- Exchange
- SUNE NYSE
- MBRX Nasdaq
- Market Cap
- SUNE 4.9M
- MBRX 4.4M
- IPO Year
- SUNE N/A
- MBRX 2016
- Fundamental
- Price
- SUNE $0.34
- MBRX $1.19
- Analyst Decision
- SUNE
- MBRX Strong Buy
- Analyst Count
- SUNE 0
- MBRX 3
- Target Price
- SUNE N/A
- MBRX $18.67
- AVG Volume (30 Days)
- SUNE 31.4M
- MBRX 16.4M
- Earning Date
- SUNE 05-14-2018
- MBRX 05-09-2025
- Dividend Yield
- SUNE N/A
- MBRX N/A
- EPS Growth
- SUNE N/A
- MBRX N/A
- EPS
- SUNE N/A
- MBRX N/A
- Revenue
- SUNE $60,929,299.00
- MBRX N/A
- Revenue This Year
- SUNE $12.33
- MBRX N/A
- Revenue Next Year
- SUNE N/A
- MBRX N/A
- P/E Ratio
- SUNE N/A
- MBRX N/A
- Revenue Growth
- SUNE N/A
- MBRX N/A
- 52 Week Low
- SUNE $0.16
- MBRX $0.40
- 52 Week High
- SUNE $315.00
- MBRX $6.24
- Technical
- Relative Strength Index (RSI)
- SUNE N/A
- MBRX 47.12
- Support Level
- SUNE N/A
- MBRX $1.05
- Resistance Level
- SUNE N/A
- MBRX $1.25
- Average True Range (ATR)
- SUNE 0.00
- MBRX 0.21
- MACD
- SUNE 0.00
- MBRX 0.01
- Stochastic Oscillator
- SUNE 0.00
- MBRX 30.40
About SUNE SUNATION ENERGY INC
SUNation Energy Inc formerly Pineapple Energy Inc provides households with sustainable solar energy, back-up power and security, control and predictability, and cost savings. The company provides a full range of installation services, including the design, engineering, procurement, permitting, construction, grid connection, warranty, monitoring and maintenance of residential solar energy systems. It also offers battery storage to customers in select markets and serves a limited number of enterprise customers.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.